SANOCHEMIA Pharmazeutika AG: Sanochemia announces veterinary asset deal

Wien (pta027/23.10.2019/13:00 UTC+2) The Management Board of Sanochemia Pharmazeutika AG (ISIN AT0000776307, ISIN DE000A1G7JQ9) announces the conclusion of an asset deal of Alvetra & Werfft GmbH (SANOCHEMIA´s veterinary division) with Inovet / Belgium.

As a result, Inovet will be able to manufacture the products, market them internationally under its own name and expand them further through its own sales network.

SANOCHEMIA receives payments in form of milestones for the license transfer and royalties on future sales. The companies have agreed confidentiality on the amount of payments.

About Inovet:
Inovet is a family-owned veterinary pharmaceutical company active worldwide, dedicated to research, production and marketing of veterinary pharmaceuticals and animal health products.
The activities are coordinated from the headquarters in Belgium, with a state-of-the-art production facility in the North of France and a commercial hub in Hungary.
Inovet offers over 160 different veterinary medicines and over 1,800 international marketing authorizations, under the umbrella of two leading veterinary brands: VMD® Livestock pharma and Biové® Laboratoires. (www.inovet.eu)

Inovet
Moons Jan, CEO
Info@inovet.eu
www.inovet.eu

(end)

Emitter:	SANOCHEMIA Pharmazeutika AG Boltzmanngasse 11 1090 Wien Austria
Contact Person:	Bettina Zuccato
Phone:	+43 1 3191456-336
E-Mail:	b.zuccato@sanochemia.at
Website:	www.sanochemia.at
ISIN(s):	AT0000776307 (Share)
Stock Exchange(s):	Free Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart; Vienna Stock Exchange (Direct Market Plus)